Nxera Pharma said it will receive a US$10 million milestone payment from AbbVie as part of their ongoing neurological-disease collaboration, representing the fourth milestone achieved to date. The announcement is a modest positive catalyst, indicating continued program progress and near-term funding support.
Nxera Pharma said it will receive a US$10 million milestone payment from AbbVie as part of their ongoing neurological-disease collaboration, representing the fourth milestone achieved to date. The announcement is a modest positive catalyst, indicating continued program progress and near-term funding support.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
